Shares of Lexicon Pharmaceuticals tanked nearly 33.6% as of 11:30 am ET after the drug company’s sotagliflozin drug candidate received a negative vote by a US Food and Drug Administration (FDA) panel, ...

Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel ...

While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external ...

Lexicon Pharmaceuticals shares have been halted all day as a Food and Drug Administration advisory committee was scheduled to vote on Zynquista as an adjunct to insulin therapy for glycemic control in ...

Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

The committee was not convinced that the benefit of Zynquista outweighed the risk in adults with type 1 diabetes and chronic ...

Lexicon还与Viatris签订了独家许可协议，授权后者在美国和欧洲以外地区商业化sotagliflozin，Viatris支付了$25 million的预付款，并有可能获得额外的里程碑付款。分析师公司Piper Sandler和H.C. Wainwright对Lexicon保持积极评级，表明公司药物的潜力。

Lexicon did manage to get approval for type 1 diabetes in Europe, but the product was never launched there for commercial ...

H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on LXRX stock, giving a Buy rating on October 17. Joseph ...

Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report) today. The company’s ...

Legendary artist Greg Hildebrandt, known for his work on Star Wars, Lord of the Rings, Marvel, and Magic: The Gathering, ...